单剂DNA新冠疫苗在已接种或感染成人中的安全性和持久免疫应答:一项1期研究
该开放标签1期概念验证研究评估了DNA疫苗IMNN-101在既往接种或感染SARS-CoV-2的健康成人中的安全性和免疫原性。受试者单次肌注0.5 mg、1.0 mg或2.0 mg疫苗(每组8人),67%(16/24)出现轻中度反应原性事件,未报告心肌炎或心包炎。免疫后针对XBB.1.5等流行变异株的中和抗体滴度升高2-3倍并维持6个月,显示良好安全性和持久体液免疫应答。
要点
- 单剂IMNN-101 DNA疫苗在既往接种或感染成人中安全性良好,未报告心肌炎或心包炎。
- 免疫后中和抗体滴度针对XBB.1.5等变异株升高2-3倍,并维持至6个月随访。
核心结论
- PlaCCine基础DNA疫苗IMNN-101单剂接种在既往接种或感染SARS-CoV-2成人中显示良好安全性和持久体液免疫应答。
研究设计与样本
- 开放标签1期概念验证研究,受试者为既往接种或感染SARS-CoV-2的健康成人,单次肌注0.5 mg、1.0 mg或2.0 mg IMNN-101,每组8人。
主要发现
- 67%(16/24)受试者出现轻中度反应原性事件,包括注射部位压痛、硬结、疼痛、红斑、肿胀、瘙痒及疲劳、肌痛、头痛、恶心/呕吐。
- 免疫后针对XBB.1.5及其他流行SARS-CoV-2变异株的中和抗体滴度升高2-3倍,并在6个月随访期间维持。
临床怎么用
- PlaCCine疫苗热稳定、无需设备或病毒递送,为免疫接种提供了可行的替代途径。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
An open label Phase-1 proof-of-concept study evaluated the safety and immunogenicity of IMNN-101, a DNA vaccine based on an expression plasmid and a synthetic delivery carrier (the PlaCCine vaccine), in healthy human adults previously vaccinated or infected with SARS-CoV-2. Study participants received a single intramuscular dose of 0.5 mg, 1.0 mg, or 2.0 mg of IMNN-101 DNA vaccine (n = 8 participants per group). Mild to moderate reactogenicity events were observed in 67% (16/24) of participants, including tenderness, hardening, pain, redness, swelling, and itching at the injection site, as well as fatigue, muscle aches, headache, and nausea/vomiting. Fourteen grade 1 or 2 treatment-emergent adverse events were reported: none of those attributed to IMNN-101. There were no reports of myocarditis or pericarditis. The immunization with IMNN-101 resulted in an increase in neutralizing antibody (NAb) titers against XBB.1.5 and other circulating variants of SARS-CoV-2, with 2-3-fold increase in NAb titers that were maintained during the 6-month follow up. This first-in-human evaluation of a PlaCCine-based DNA vaccine demonstrates a favorable safety profile and durable humoral immune response. The PlaCCine vaccine is thermostable, does not require a device or virus for delivery, and offers a viable alternative approach to immunization.
引用
- Anwer K, Musso L, Lasrado N, et al. Safe and durable immune responses to a single dose DNA COVID-19 vaccine in previously vaccinated or SARS-CoV-2-infected adults: A phase 1 study. Vaccine. 2026. PMID: 41722533. doi:10.1016/j.vaccine.2026.128357
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。